References
- Cell A R J F I, Biology D. Organoid models of glioblastoma to study brain tumor stem cells. Front Cell Dev Biol. 2020;8:220–8.
- Maeshima R, Moulding D, Stoker AW, Hart SL. MYCN silencing by rna interference induces neurogenesis and suppresses proliferation in models of neuroblastoma with resistance to retinoic acid. Nucleic Acid Ther. 2020;30(4):237–248. doi:https://doi.org/10.1089/nat.2019.0831.
- Lu QR, Qian L, Zhou X. Developmental origins and oncogenic pathways in malignant brain tumors. Wiley Interdiscip Rev Dev Biol. 2019;8(4):e342. doi:https://doi.org/10.1002/wdev.342.
- Song X, Selorm Fiati Kenston S, Zhao J, Yang D, Gu Y. Roles of FoxM1 in cell regulation and breast cancer targeting therapy. Med Oncol. 2017;34(3):41–51. doi:https://doi.org/10.1007/s12032-017-0888-3.
- Bella L, Zona S, de Moraes G, Lam EW-F. FOXM1: a key oncofoetal transcription factor in health and disease. Semin Cancer Biol. 2014; 29:32–9. doi:https://doi.org/10.1016/j.semcancer.2014.07.008.
- Dai J, Yang L, Wang J, Xiao Y, Ruan Q. Prognostic value of FOXM1 in patients with malignant solid tumor: a meta-analysis and system review. Dis Markers. 2015;2015:352478–87. doi:https://doi.org/10.1155/2015/352478.
- Wang and Zebin. Emerging roles of forkhead box protein FoxM1 in cancer: implications in tumorigenicity and drug therapy. Dissertations & Theses – Gradworks. 2013.
- Jiang Dai N, Su Q, Fu X, Feng J, Peng XJ. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior. Mol Biol Rep. 2020;47(6):4587–629. doi:https://doi.org/10.1007/s11033-020-05435-1.
- Sharma V, Sharma AK, Punj V, Priya P. Recent nanotechnological interventions targeting PI3K/Akt/mTOR pathway: a focus on breast cancer. Semin Cancer Biol. 2019;59 (59):133–46. doi:https://doi.org/10.1016/j.semcancer.2019.08.005.
- Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med. 2016;67(1):11–28. doi:https://doi.org/10.1146/annurev-med-062913-051343.
- Xiao Y, Yu Y, Jiang P, Li Y, Wang C, Zhang R. The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis. Cell Oncol (Dordr). 2020;43(4):669–80. doi:https://doi.org/10.1007/s13402-020-00514-8.
- Zhang B, Liu LL, Mao X, Zhang DH. Effects of metformin on FOXM1 expression and on the biological behavior of acute leukemia cell lines. Mol Med Rep. 2014;10(6):3193–8. doi:https://doi.org/10.3892/mmr.2014.2629.
- Li R, Yin F, Guo YY, Zhao KC, Ruan Q, Qi YM. Knockdown of ANRIL aggravates H2O2-induced injury in PC-12 cells by targeting microRNA-125a. Biomed Pharmacother. 2017;92:952–61. doi:https://doi.org/10.1016/j.biopha.2017.05.122.
- Yao W, Li K, Zheng S, Xiao X, Ma Y, Zhai X. Knockdown of β-catenin expression inhibits neuroblastoma cell growth in vitro and in vivo. J Pediatr Surg. 2013;48(12):2466–73. doi:https://doi.org/10.1016/j.jpedsurg.2013.08.024.
- Zhao Q, Liu Y, Zhang Y, Meng L, Wei J, Wang B, Wang H, Xin Y, Dong L, Jiang X. Role and toxicity of radiation therapy in neuroblastoma patients: a literature review. Crit Rev Oncol Hematol. 2020; 149:102924–49. doi:https://doi.org/10.1016/j.critrevonc.2020.102924.
- Scriba LD, Bornstein SR, Santambrogio A, Mueller G, Huebner A, Hauer J, Schedl A, Wielockx B, Eisenhofer G, Andoniadou CL, et al. Cancer stem cells in pheochromocytoma and paraganglioma. Front Endocrinol (Lausanne). 2020;11:79. doi:https://doi.org/10.3389/fendo.2020.00079.
- Casey DL, Cheung NV. Immunotherapy of pediatric solid tumors: treatments at a crossroads, with an emphasis on antibodies. Cancer Immunol Res. 2020; 8(2):161–6. doi:https://doi.org/10.1158/2326-6066.CIR-19-0692.
- Szanto CL, Cornel AM, Vijver SV, Nierkens S. Monitoring immune responses in neuroblastoma patients during therapy. Cancers. 2020;12(2):519–38. doi:https://doi.org/10.3390/cancers12020519.
- Somasundaram DB, Subramanian K, Aravindan S, Yu Z, Natarajan M, Herman T, Aravindan N. De novo regulation of RD3 synthesis in residual neuroblastoma cells after intensive multi-modal clinical therapy harmonizes disease evolution. Sci Rep. 2019;9(1):11766. doi:https://doi.org/10.1038/s41598-019-48034-2.
- Southgate HED, Chen L, Curtin NJ, Tweddle DA. Targeting the DNA damage response for the treatment of high risk neuroblastoma. Front Oncol. 2020;10:371. doi:https://doi.org/10.3389/fonc.2020.00371.
- Chang-Panesso M, Kadyrov FF, Lalli M, Wu H, Ikeda S, Kefaloyianni E, Abdelmageed MM, Herrlich A, Kobayashi A, Humphreys BD. FOXM1 drives proximal tubule proliferation during repair from acute ischemic kidney injury. J Clin Invest. 2019;129(12):5501–17. doi:https://doi.org/10.1172/JCI125519.
- Sun HL, Men JR, Liu HY, Liu MY, Zhang HS. FOXM1 facilitates breast cancer cell stemness and migration in YAP1-dependent manner. Arch Biochem Biophys. 2020;685:108349. doi:https://doi.org/10.1016/j.abb.2020.108349.
- Kyuno T, Kohno T, Konno T, Yamaguchi H, Kyuno D, Imamura M, Kimura Y, Kojima T, Takemasa I. Glucose-dependent FOXM1 promotes epithelial-to-mesenchymal transition via cellular metabolism and targeting snail in human pancreatic cancer. Pancreas. 2020;49(2):273–80. doi:https://doi.org/10.1097/MPA.0000000000001485.
- Ahmed F. Integrated network analysis reveals FOXM1 and MYBL2 as key regulators of cell proliferation in non-small cell lung cancer. Front Oncol. 2019;9:1011. doi:https://doi.org/10.3389/fonc.2019.01011.
- Wei Y, Wang Z, Zong Y, Deng D, Chen P, Lu J. LncRNA MFI2-AS1 promotes HCC progression and metastasis by acting as a competing endogenous RNA of miR-134 to upregulate FOXM1 expression. Biomed Pharmacother. 2020;125:109890. doi:https://doi.org/10.1016/j.biopha.2020.109890.
- Goda C, Balli D, Black M, Milewski D, Le Ustiyan TV, Ren X, Kalinichenko VV, Kalin TV. Loss of FOXM1 in macrophages promotes pulmonary fibrosis by activating p38 MAPK signaling pathway. PLoS Genet. 2020;16(4):e1008692. doi:https://doi.org/10.1371/journal.pgen.1008692.
- Yu Z, Zhan C, Du H, Zhang L, Liang C, Zhang L. Baicalin suppresses the cell cycle progression and proliferation of prostate cancer cells through the CDK6/FOXM1 axis. Mol Cell Biochem. 2020;469(1–2):1–10. doi:https://doi.org/10.1007/s11010-020-03739-1.
- Higurashi M, Maruyama T, Nogami Y, Ishikawa F, Yoshida Y, Mori K, Fujita KI, Shibanuma M. High expression of FOXM1 critical for sustaining cell proliferation in mitochondrial DNA-less liver cancer cells. Exp Cell Res. 2020;389(1):111889. doi:https://doi.org/10.1016/j.yexcr.2020.111889.
- Pan C, Chen Y, Xu T, Wang J, Li D, Han X. Chronic exposure to microcystin-leucine-arginine promoted proliferation of prostate epithelial cells resulting in benign prostatic hyperplasia. Environ Pollut. 2018;242(Pt B):1535–45. doi:https://doi.org/10.1016/j.envpol.2018.08.024.
- Cao J, Jiang X, Peng X. Forkhead box M1 inhibits endothelial cell apoptosis and cell-cycle arrest through ROS generation. Int J Clin Exp Pathol. 2018;11(10):4899–907.
- Fuller MS, Majumder K, Pintel DJ. Minute virus of mice inhibits transcription of the cyclin B1 gene during infection. Virology. 2017;91(14):e00428-17.
- Gérard C, Goldbeter A. From quiescence to proliferation: Cdk oscillations drive the mammalian cell cycle. Front Physiol. 2012;3:413–30. doi:https://doi.org/10.3389/fphys.2012.00413.
- Wei X, Li X, Yan W, Zhang X, Sun Y, Zhang F. SKP2 promotes hepatocellular carcinoma progression through nuclear AMPK-SKP2-CARM1 signaling transcriptionally regulating nutrient-deprived autophagy induction. Cell Physiol Biochem. 2018;47(6):2484–97. doi:https://doi.org/10.1159/000491622.
- Zhang W, Cao L, Sun Z, Xu J, Tang L, Chen W, Luo J, Yang F, Wang Y, Guan X. Skp2 is over-expressed in breast cancer and promotes breast cancer cell proliferation. Cell Cycle. 2016;15(10):1344–51. doi:https://doi.org/10.1080/15384101.2016.1160986.
- Wang Z, Park HJ, Carr JR, Chen YJ, Zheng Y, Li J, Tyner AL, Costa RH, Bagchi S, Raychaudhuri P. FoxM1 in tumorigenicity of the neuroblastoma cells and renewal of the neural progenitors. Cancer Res. 2011;71(12):4292–302. doi:https://doi.org/10.1158/0008-5472.CAN-10-4087.
- Zhang M, Liu Y, Gao Y, Li S. Silibinin-induced glioma cell apoptosis by PI3K-mediated but Akt-independent downregulation of FoxM1 expression. Eur J Pharmacol. 2015;765:346–54. doi:https://doi.org/10.1016/j.ejphar.2015.08.057.
- Miyashita A, Fukushima S, Nakahara S, Yamashita J, Tokuzumi A, Aoi J, Ichihara A, Kanemaru H, Jinnin M, Ihn H. Investigation of FOXM1 as a potential new target for melanoma. Plos One. 2015;10(12):e0144241. doi:https://doi.org/10.1371/journal.pone.0144241.